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ASA-NeuAc2en, a photoreactive arylazide derivative of sialic acid, is shown to be a powerful competitive inhibitor of lysosomal neuraminidase 
from bovine testis (KS x 21 FM). Photoaffinity labeling and partial purification of preparations containing this lysosomal neuraminidase activity 
result in specifically and non-specifically labeled polypeptides. Only labeling in a 55 kDa polypeptide is found to be specific, since it could be pre- 
vented by the competitive neuraminidase inhibitor NeuAcZen. We conclude that the 55 kDa polypeptide in the bovine testis p-galactosidase/neu- 
raminidase/protective protein complex contains the catalytic site of neuraminidase. 
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1. INTRODUCTION 
In the inherited metabolic disorder sialidosis the in- 
tralysosomal degradation of sialoglycoconjugates i im- 
paired due to a deficiency of the acid hydrolase neura- 
minidase (sialidase EC 3.2.1.18) [l-3]. In galac- 
tosialidosis a combined deficiency of neuraminidase 
and ,8-galactosidase xists [4,5]. The latter disease is 
caused by a mutation in the ‘protective protein’, which 
protects ,&galactosidase from intralysosomal degrada- 
tion and is essential for neuraminidase activity [6]. No 
information is available about the molecular defect in 
sialidosis. 
Active neuraminidase has been isolated from bovine 
testis and human placenta as a high molecular mass 
complex with&galactosidase and the protective protein 
[7,8]. Partial disruption of the complex with KSCN 
results in the dissociation of the neuraminidase poly- 
peptide from the complex. The unassociated neur- 
aminidase polypeptide has no enzymatic activity [9]. 
Reconstitution experiments have shown that, in vitro, 
association of the neuraminidase polypeptide with the 
protective protein generates a labile form of neuramini- 
dase activity. This activity is stabilized by ,&galacto- 
sidase [lo]. Most likely the neuraminidase polypeptide 
contains the catalytic site. 
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To investigate the catalytic site of neuraminidases, we 
have recently synthesized the radioiodinatable, photo- 
reactive affinity probe ASA-NeuAQen. This probe was 
successfully used to label the active site of a bacterial 
neuraminidase [l 11. In the present study we have used 
ASA-NeuAc2en to label the neuraminidase polypeptide 
in the lysosomal ,&galactosidase/neuraminidase/pro- 
tective protein complex from bovine testis. 
2. MATERIALS AND METHODS 
2.1. Materials 
ASA-NeuAQen and [“‘I]IASA-NeuAc2en were prepared as 
described previously [ 111. The ,&galactosidase/neuraminidase/pro- 
tective protein complex was purified from bovine testis as reported by 
Verheijen et al. [7]. 
2.2. Photoaffinity labeling and further purification of bovine testis 
neuraminidase 
[‘251]IASA-NeuAc2en (150 pl; 25 pM; specific activity 4.7 
Ci/mmol) was dried under Nz in absence or presence of 20~1 100 mM 
NeuAcZen. The dried material was dissolved in 200 pl bovine testis 
complex (200 pg; specific activity 113 mU/mg) in 20 mM sodium 
acetate, 100 mM NaCl, pH 5.2 (Buffer A), containing 1% Triton 
X-100 and incubated for 5 min at room temperature (final concentra- 
tion of [iZ51]IASA-NeuAc2en 18.75 FM). After cooling on ice for 30 
s and addition of ,f?-mercaptoethanol (final concentration 100 mM), 
samples were exposed to 254 nm UV-light for 1 min at a distance of 
1 cm. Unbound label was removed by rapid gel filtration through a 
Sephadex G-50 medium spin column [12], equilibrated with buffer A 
containing 1% Triton X-100. Under these conditions, no detectable 
UV-induced protein-protein crosslinking or ASA-NeuAc2en-specific 
inactivation of neuraminidase was observed. 
After photoaffinity labeling, neuraminidase was further purified by 
sucrose density gradient centrifugation on a linear 20-40% sucrose 
gradient in buffer A (15 h; 150 000 x g; 4°C). Fractions containing 
neuraminidase activity were pooled. Protein was precipitated with 
10% TCA and analyzed on a 11% SDS-polyacrylamide gel as describ- 
ed by Laemmli [13]. Photoaffinity-labeled proteins were visualized by 
autoradiography of the dried gel. 
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2.3. Enzymatic assays 
Neuraminidase and ,&galactosidase activities were measured with 
the corresponding 4-methylumbelliferyl substrates as described (141. 
Kinetic experiments were performed as previously reported [ll] in 
either neuraminidase assay buffer (125 mM sodium acetate, pH 4.3) 
or in buffer A. Protein concentrations were determined according to 
Lowry et al. [15]. 
3. RESULTS AND DISCUSSION 
To generate optimal conditions for successful photo- 
affinity labeling of a mammalian lysosomal neura- 
minidase two considerations were made. First, mam- 
malian neuraminidases are known to be very labile [ 161. 
We have performed our experiments with the ,8-galac- 
tosidase/neuraminidase/protective protein complex 
isolated from bovine testis [7], since among the purified 
lysosomal neuraminidases it is the most stable form 
available. Secondly, photoaffinity labeling experiments 
with complex protein mixtures are often hindered by a 
large extent of non-specific labeling [17]. To reduce 
non-specific labeling we have used the scavenger ,8- 
mercaptoethanol [17]. To increase the ratio between 
specifically and non-specifically labeled proteins we 
have partially purified the neuraminidase after the 
labeling reaction. 
ASA-NeuAc2en is a derivative of NeuAc2en, a po- 
tent competitive inhibitor of mammalian neuramini- 
dases [ 181. To investigate whether introduction of the 
photoreactive group in NeuAc2en has reduced its af- 
finity for the bovine testis neuraminidase, Ki values for 
ASA-NeuAc2en and NeuAc2en were compared in 
kinetic experiments with the purified complex. Under 
standard assay conditions the K, for 4-MU-NeuAc is 
115 PM. The Ki values for ASA-NeuAc2en and 
NeuAc2en are 21 and 16 PM, respectively (Fig. 1A). 
This demonstrates that despite the presence of the 
arylazide group ASA-NeuAc2en is efficiently recogniz- 
ed by the bovine testis neuraminidase. 
To avoid the risk of protein loss due to buffer 
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Fig. 1 Inhibition kinetics of lysosomal bovine testis neuraminidase Fig. 3 Photoaffinity labeling of bovine testis neuraminidase. Bovine 
with NeuAcZen and ASA-NeuAQen. Purified bovine testis complex testis&galactosidase/neuraminidase/protective protein complex (200 
(8 mu/ml) was incubated with varying concentrations of 4-MU- cg) was photoaffinity-labeled with [‘251]IASA-NeuAc2en. Neurami- 
NeuAc at pH 4.3 (panel A) or 5.2 (panel B) in absence of inhibitor nidase was partially purified by sucrose density centrifugation and 
(0) or in presence of 30 pM NeuAcZen (A) or ASA-NeuAc2en (0). 
The enzyme activity is plotted as double reciprocal against the 
analyzed on a 11 % SDS-polyacrylamide gel. Lane 1: labeling per- 
formed in absence of inhibitor; lane 2: labeling performed in presence 
substrate concentration. of 10 mM NeuAcZen. 
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Fig. 2 Sucrose density centrifugation of 2OOpg purified bovine testis 
&galactosidase/neuraminidase/protective protein complex on a 
20-40’70 linear sucrose gradient. (M) Neuraminidase activity, 
(O---O) &galactosidase activity. 
ing reaction can be performed in the buffer used for the 
purification of the complex. When kinetic experiments 
were performed in buffer A (Fig. lB), the affinity of 
bovine testis neuraminidase for 4-MU-NeuAc (K, 104 
PM), ASA-NeuAc2en (Ki 25 PM), and NeuAc2en (Ki 16 
PM) is not altered. Also, addition of the scavenger ,&- 
mercaptoethanol had no effect on the affinity (data not 
shown). The ability to perform the photoaffinity label- 
ing reaction in buffer A greatly facilitates the further 
purification of neuraminidase after labeling. 
For glycoprotein preparations from human placenta 
sucrose density gradient centrifugation has been used to 






Volume 277, number 1,2 FEBSLETTERS December 1990 
separate complexes with neuraminidase and ,8-galac- 
tosidase activity from complexes only containing ,8- 
galactosidase activity [8]. Fig. 2 shows the distribution 
of neuraminidase and ,8-galactosidase activity after cen- 
trifugation of 200 pg bovine testis complex on a 20- 
40% linear sucrose gradient. With this method the 
neuraminidase activity can be separated from the ma- 
jority of ,&galactosidase activity. 
Purified bovine testis complex was photoaffinity- 
labeled with [1251]IASA-NeuAc2en and neuraminidase 
was further purified by sucrose density centrifugation. 
After SDS-polyacrylamide gel electrophoresis, radio- 
labeled proteins with molecular masses of 64,55, 32 and 
20 kDa were observed (Fig. 3, lane 1). The pattern cor- 
responds with that of the purified complex after 
Coomassie staining [7]. The 64 kDa protein is &galac- 
tosidase, whereas the 32 and 20 kDa proteins are the 
two polypeptides of the heterodimeric protective pro- 
tein [7,19]. When labeling is performed in the presence 
of the competitive inhibitor NeuAc2en at a concentra- 
tion that prevents specific labeling (Fig. 3, lane 2), only 
labeling of the 55 kDa protein is prevented. Identical 
results were obtained when total glycoprotein prepara- 
tions from bovine testis were used, providing that after 
labeling neuraminidase was further purified by isola- 
tion of the complex and sucrose density gradient cen- 
trifugation (data not shown). This demonstrates that 
ASA-NeuAQen can also be used with less pure neura- 
minidase preparations. We conclude that the 55 l@a 
protein is the neuraminidase polypeptide, specifically 
labeled at the active site. This protein is smaller than the 
66 kDa neuraminidase polypeptide observed in human 
placenta [IO]. A comparative biochemical study of both 
polypeptides is in progress. 
After the successful application of ASA-NeuAc2en 
for the labeling of a bacterial neuraminidase [ 1 I], we 
have now extended its use for the labeling of a mam- 
malian lysosomal neuraminidase. ASA-NeuAc2en 
enables further localization of catalytic site sequences at 
the peptide level [ Ill. This opens new possibilities for 
obtaining detailed information about the active site of 
the lysosomal neuraminidase and the molecular defect 
in sialidosis. 
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